SecBot SecBot
SECBOTREPLAY Home › Report › TRVI

TRVI · Trevi Therapeutics priced a $150 million follow-on offering just one…

Trevi Therapeutics, Inc. · 8-K filed Apr 17, 2026 at 08:06 ET

At the news

BEARISHIMPACT 7/10

8-K filed Apr 17, 2026 at 08:06 ET

Trevi Therapeutics priced a $150 million follow-on offering just one day after reporting earnings, raising concerns about capital needs despite improved cash runway. The company provided updates on its Phase 3 trials for Haduvio, with topline results expected in 2027-2028.

  • Priced $150 million follow-on offering at $13.00/share, one day after earnings report
  • Cash runway extended to 2029 from $171.8 million as of March 31, 2026
  • Net proceeds estimated at $141.1 million after fees
  • Company maintains it will fund development through FDA approval for IPF indication

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access